Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotech company focused on developing medicines that correct abnormal gene expression, has announced its participation in three upcoming investor conferences in September 2025.
The company will attend Citi's 2025 Biopharma Back to School Summit on September 3, the 2025 Wells Fargo Healthcare Conference on September 4, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8. Management will conduct one-on-one meetings at all three events.
Foghorn's Gene Traffic Control® platform focuses initially on oncology applications, aiming to develop treatments for a broad spectrum of diseases.
Foghorn Therapeutics (Nasdaq: FHTX), una società biotech in fase clinica focalizzata sullo sviluppo di farmaci che correggono l'espressione genica anomala, ha annunciato la sua partecipazione a tre prossimi convegni per investitori a settembre 2025.
La società parteciperà al Citi's 2025 Biopharma Back to School Summit il 3 settembre, al 2025 Wells Fargo Healthcare Conference il 4 settembre e al Morgan Stanley 23rd Annual Global Healthcare Conference l'8 settembre. Il management terrà incontri one-to-one in tutti e tre gli eventi.
La piattaforma Gene Traffic Control® di Foghorn si concentra inizialmente sulle applicazioni in oncologia, con l'obiettivo di sviluppare terapie per un ampio spettro di malattie.
Foghorn Therapeutics (Nasdaq: FHTX), una biotecnológica en fase clínica centrada en desarrollar medicamentos que corrigen la expresión génica anómala, ha anunciado su participación en tres próximas conferencias para inversores en septiembre de 2025.
La compañía asistirá al Citi's 2025 Biopharma Back to School Summit el 3 de septiembre, al 2025 Wells Fargo Healthcare Conference el 4 de septiembre y al Morgan Stanley 23rd Annual Global Healthcare Conference el 8 de septiembre. La dirección mantendrá reuniones one-to-one en los tres eventos.
La plataforma Gene Traffic Control® de Foghorn se orienta inicialmente a aplicaciones en oncología, con la meta de desarrollar tratamientos para un amplio espectro de enfermedades.
Foghorn Therapeutics (나스닥: FHTX)는 비정상적인 유전자 발현을 교정하는 약물 개발에 중점을 둔 임상 단계 바이오텍으로, 2025년 9월 개최되는 세 건의 투자자 컨퍼런스에 참가한다고 발표했습니다.
회사는 9월 3일 Citi's 2025 Biopharma Back to School Summit, 9월 4일 2025 Wells Fargo Healthcare Conference, 9월 8일 Morgan Stanley 23rd Annual Global Healthcare Conference에 참석할 예정이며, 경영진은 세 행사 모두에서 1:1 미팅을 진행합니다.
Foghorn의 Gene Traffic Control® 플랫폼은 초기에는 암(종양학) 적용에 중점을 두고 있으며, 넓은 범위의 질환에 대한 치료제 개발을 목표로 하고 있습니다.
Foghorn Therapeutics (Nasdaq: FHTX), une société de biotechnologie en phase clinique spécialisée dans le développement de médicaments corrigeant l'expression génique anormale, a annoncé sa participation à trois prochaines conférences investisseurs en septembre 2025.
La société assistera au Citi's 2025 Biopharma Back to School Summit le 3 septembre, à la 2025 Wells Fargo Healthcare Conference le 4 septembre et à la Morgan Stanley 23rd Annual Global Healthcare Conference le 8 septembre. La direction tiendra des réunions individuelles lors des trois événements.
La plateforme Gene Traffic Control® de Foghorn se concentre initialement sur des applications en oncologie, visant à développer des traitements pour un large éventail de maladies.
Foghorn Therapeutics (Nasdaq: FHTX), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Medikamenten zur Korrektur abnormer Genexpression konzentriert, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird am Citi's 2025 Biopharma Back to School Summit am 3. September, an der 2025 Wells Fargo Healthcare Conference am 4. September und an der Morgan Stanley 23rd Annual Global Healthcare Conference am 8. September teilnehmen. Das Management wird bei allen drei Veranstaltungen Einzelgespräche führen.
Foghorns Gene Traffic Control®-Plattform konzentriert sich zunächst auf Anwendungen in der Onkologie und zielt darauf ab, Therapien für ein breites Spektrum von Erkrankungen zu entwickeln.
- None.
- None.
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- August 27, 2025 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Citi’s 2025 Biopharma Back to School Summit, 2025 Wells Fargo Healthcare Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Citi’s 2025 Biopharma Back to School Summit
- Date: Wednesday, September 3, 2025
- Management will participate in one-on-one meetings
2025 Wells Fargo Healthcare Conference
- Date: Thursday, September 4, 2025
- Management will participate in one-on-one meetings
Morgan Stanley 23rd Annual Global Healthcare Conference
- Date: Monday, September 8, 2025
- Management will participate in one-on-one meetings
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
FAQ
When is Foghorn Therapeutics (FHTX) presenting at the Wells Fargo Healthcare Conference 2025?
What conferences will Foghorn Therapeutics (FHTX) attend in September 2025?
What is Foghorn Therapeutics' (FHTX) main technology platform?
How can investors meet with Foghorn Therapeutics (FHTX) management at these conferences?
